Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track INBX with free AI briefings, catalyst countdowns, and dilution alerts.

INBX · Inhibrx Biosciences, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$199.5M Cash on Hand
18.5mo Cash Runway
30.6% Short Interest
$258.33 Analyst Target (3)
Follow INBX by email Get an email when INBX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about INBX, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoAOptions-implied move
2027-04-14 ozekibart unresectable or metastatic conventional chondrosarcoma BLA 61% ±51% by May 21

Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What INBX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Ordastobart (INBRX-106) Head and Neck Squamous Cell Carcinoma (HNSCC) Phase 2/3 · NCT06295731 Recruiting
Carboplatin AUC-5 Solid Tumor Phase 1/2 · NCT04198766 Recruiting
Carboplatin AUC-6 Solid Tumor Phase 1/2 · NCT04198766 Recruiting
Nab-paclitaxel Solid Tumor Phase 1/2 · NCT04198766 Recruiting
Ozekibart (INBRX-109) Conventional Chondrosarcoma Phase 2 · NCT04950075 Active not recruiting
Trifluridine and Tipiracil Hydrochloride Ewing Sarcoma Phase 1 · NCT03715933 Recruiting
Irinotecan Ewing Sarcoma Phase 1 · NCT03715933 Recruiting
Enristomig (INBRX-105) Metastatic Solid Tumors Phase 1 · NCT03809624 Terminated
INBRX-101/rhAAT-Fc Alpha-1 Antitrypsin Deficiency Phase 1 · NCT03815396 Completed

Also used in these trials (approved or third-party drugs, not INBX's own candidates): Pembrolizumab, Cisplatin, Paclitaxel, Gemcitabine Hydrochloride, Pemetrexed Disodium, Temozolomide, Bevacizumab, Leucovorin, Fluorouracil, Carboplatin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

INBX holds $199.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $32.3M/quarter from operations, an estimated runway of 18.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 31 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INBX files for a raise →

👥 Who Owns INBX

Insiders 36.1% Institutions (228 holders) 63.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
Perceptive Advisors LLC Institution (13G, 5%+) 1,489,443 10.12% 2026-06-30
VIKING GLOBAL INVESTORS LP
10% owner
Insider 1,383,621 9.40% 2026-06-30
Inhibrx, Inc.
10% owner
Insider 1,157,926 7.87% 2024-05-29
Sanofi Institution (13F) 1,157,926 7.87% 2026-09-30
Morgan Stanley Institution (13G, 5%+) 1,155,416 7.85% 2025-12-31
Jon Faiz Kayyem
Director · +55,000 options
Insider 1,074,046 7.30% 2026-09-23
Mark Lappe
Chief Executive Officer, Director · +300,000 options
Insider 970,453 6.59% 2026-10-14
Schonfeld Strategic Advisors LLC Institution (13G, 5%+) 952,959 6.47% 2026-09-30
HighTower Advisors, LLC Institution (13F) 884,441 6.01% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 768,130 5.22% 2025-12-31
TIG Advisors, LLC Institution (13F) 677,789 4.61% 2026-09-30
State Street Corporation Institution (13F) 565,749 3.84% 2026-09-30

Share count 14,717,660 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-14
filed 2026-10-14
Lappe Mark
Purchase (P) 2,470 $84.07 743,018
2026-10-14
filed 2026-10-14
Lappe Mark
Purchase (P) 2,470 $85.00 745,488
2026-10-14
filed 2026-10-14
Lappe Mark
Purchase (P) 100 $85.76 745,588
2026-10-14
filed 2026-10-14
Lappe Mark
Purchase (P) 2,449 $84.07 167,449
2026-10-14
filed 2026-10-14
Lappe Mark
Purchase (P) 2,451 $85.00 169,900

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full INBX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INBX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.